Retinitis pigmentosa (RP) describes a group of genetic disorders that damage light-sensitive cells in the retina, leading to gradual vision loss over time as the cells die off. While the condition is classified as a rare disease, it is one of the most common inherited diseases of the retina, affecting between 1 in 3500 to 1 in 4000 Canadians.RP is often referred to as an inherited retinal disease, meaning that it is passed along genetic lines and inherited from ones parents. Though it is usually diagnosed during childhood or adolescence, a minority of patients report symptoms later in life.
Specialized cells called photoreceptors are responsible for absorbing light and translating it into signals that are interpreted by the brainit is these essential cells that gradually die off as a result of RP. The cells come in two varieties: rod cells and cone cells. Rod photoreceptors are responsible for peripheral and night vision, while cone photoreceptors are responsible for central, high-acuity vision as well as detail and colour. Since it is the rod cells that are first damaged by RP, peripheral and night vision are affected during the early stages of the disease, followed by a narrowing of the visual field, often referred to as a progressive form of tunnel vision. The death of rod cells eventually affects the cone cells as well, leading to the loss of central vision and often resulting, during the later stages of the disease, in near or total blindness. The length of this process varies from individual to individual.
RP was originally considered a single disease, but after decades of researchincluding research funded by the FFBwe now know that there are several forms of RP, and that these forms involve mutations in any one of more than 64 different genes. The gene or genes affected determine the disease type and symptoms.
There are several different ways that RP can be inherited, which is usually described as the inheritance pattern. The different RP inheritance patterns include: autosomal dominant, autosomal recessive, and x-linked recessive. A genetic counsellor can talk with you about your family history and determine which of these patterns is associated with your vision loss. With this information, the genetic counsellor may be able to tell you more about how your condition will progress, and give you and your family information about the risks of vision loss for other family members. To learn more about genetic testing for RP, please consult the FFB resource Everything You Need to Know about Genetic Testing.
Typically, each person with RP only has damage in one pair of genes. Scientists have now identified more than 64 genes that can have mutations that cause RP. It is likely that mutations in more than 100 different genes will eventually be identified. Because so many RP-causing gene mutations are still unknown, there is about a 50:50 chance that genetic testing will provide a definitive result. Given your family history and the inheritance pattern of your RP, your genetic counsellor will be able to advise you about the likelihood that a genetic test will provide a definitive result.
Different genetic mutations can damage the retina or impair its function in different ways; for example, some mutations affect how the retina processes nutrients, while others damage the photoreceptors. Its important to identify the specific gene and mutation, because many treatments being developed for RP will be for particular genetic types.
Content on this page was written by Dr. Chad Andrews and Dr. Mary Sunderland, and was most recently updated on August 23, 2018. An earlier version of the content was approved by Dr. Jane Green and Dr. Bill Stell.
The most common early symptom of RP is difficultly seeing at night and in low-light conditionsthis is called nyctalopia or night blindness. The loss of peripheral vision is also a common first symptom, and is often experienced alongside nyctalopia. As RP progresses, peripheral vision slowly diminishes, resulting in a narrow field of view or tunnel vision. By age 40, many people with RP are legally blind, with a severely constricted field of vision, although many may retain the ability to read and recognize faces. Uncomfortable sensitivity to light and glare is common, as is photopsia (seeing flashes of light or shimmering). RP can also cause a loss of visual acuity (the ability to see clearly), but the onset is more variable. Some patients retain normal visual acuity, even when their vision is reduced to a small central island; others lose acuity much earlier in the course of disease. Eventually, however, most people with RP will begin to lose central vision and some will lose all light perception.
An ophthalmologist may suspect RP on the basis of a persons symptoms and the findings of a simple eye examination. Two tests are used to clarify the diagnosis:
Currently, there is only a single approved treatment for a very rare form of RP on the market in the United States: a gene therapy called Luxturna, which can halt vision loss and even restore some sight in individuals with a biallelic mutation of their RPE65 gene (manifesting as either RP or Leber congenital amaurosis). Though the number of patients with this mutation is small, the medical effectiveness of Luxturna and its materialization as a pharmaceutical product demonstrate that there is significant potential for gene therapy to treat other forms of RP in the future.
Read Our Story About The Approval of Luxturna
Clinical trials are essential to the scientific process of developing new treatments: they test the viability and safety of experimental drugs and techniques, called interventions, on human beings. While there is no guarantee that enrolling in a clinical trial will provide any medical benefit, some patients do experience positive results after receiving an experimental therapy.
Read Our Clinical Trials Guide
The website clinicaltrials.gov is a centralized database of clinical trials that are offered globally. But as the disclaimer on the sites home page states, there is no guarantee that a listed trial has been evaluated or approvedthe National Institutes of Health runs the site but does not vet its content. This means that there could be bogus or dangerous trials listed that are preying on patients. It is essential that you discuss a clinical trial with your ophthalmologist before enrolling, and that you pay close attention to enrollment criteria.
If you are interested in exploring what is available on the site you can click on the button below, which will take you to clinicaltrials.gov and initiate a search for trials relevant for patients living with RP.
CLINICAL TRIALS FOR Retinitis Pigmentosa
For individuals living with an inherited retinal disease (a disease caused by a genetic mutation), participation in a clinical trial could be a logical next-step (for a description of clinical trials, see above). But in Canada there is no centralized, guided mechanism for enrolling in a trial; with this in mind, the Foundation Fighting Blindness has developed a secure medical database of Canadian patients living with inherited retinal diseases: we call it the Patient Registry.
By enrolling in the Patient Registry, your information will become a part of this essential Canadian database that can be used to help connect you to a relevant clinical trial. The availability of relevant trials depends on a number of factors, so this tool provides no guarantees, but signing onto it will put you in a position to be connected to something appropriate. It is also a way of standing up and being counted: the more individuals enrolled in the Patient Registry, the better our chances of showing policymakers that there is a significant need for new treatments for inherited retinal diseases. The Patient Registry also helps to drive more sight-saving research!
You can begin the process of enrolling in the Patient Registry by clicking the button below.
Patient Registry Enrollment
The Foundation Fighting Blindness is committed to advancing the most promising sight-saving research, and has invested over $33 million into cutting-edge science since the organization was founded. Recognizing that science is tied to policy frameworks, the Foundation is also actively involved in health policy activities across Canada.
Many research groups are working to develop treatments and cures for RP. Experimental treatments can be divided into three broad categories:
Protective therapies aim to stop (or at least slow) the damage caused by genetic mutations. Often protective therapies are not specific to one mutation, but may benefit people with many types of RP. These include treatments to stop the process of photoreceptor death (apoptosis), as well as cell-derived therapies that aim to help photoreceptors survive.
Some protective therapies aim specifically to prevent the death of cone cells in RP and thus, the loss of central vision in later stages of the disease.
Corrective therapies aim to reverse the underlying genetic defect that causes vision loss. If these therapies are successful they might prevent a person who is treated when first diagnosed, from ever developing vision loss. Corrective therapies might also help slow the disease in people whose vision has already been affected, especially in the earlier stages. The corrective therapies being developed now are specific to certain forms of recessively inherited RP. Gene therapies, which replace a non-functioning gene, are one type of corrective therapy. Clinical trials of gene therapies for several types of RP are underway, and the results so far are encouraging.
Sight-restoring therapies are also a growing area of research success. These therapies are intended for people who have already lost all, or much, of their vision. Stem cell therapies aim to replace the retinas lost photoreceptors. There are promising early results with stem cell trials involving other retinal degenerative diseases; trials with RP are on the horizon. Retinal prosthetics, such as the Arugus II or Bionic Eye, use computer technology to generate vision. The Foundation Fighting Blindness helped to support the first Canadian trial of the Argus II and continues to work closely with health policy experts across Canada to ensure that patients who could benefit from the Argus II device have access to this innovative treatment. Drug and gene therapies are also being developed that may give non-photoreceptor nerve cells in the retina the capacity to sense light.
Thanks to our generous donors, we are funding ground-breaking research in these areas. Click on the button below to review the full list of FFB-funded projects:
On the right side of this webpage, you will find an updating list of stories that detail new research and health policy developments relevant for individuals affected by RP.
The page you are now on provides information on RP, but the Foundation Fighting Blindness has developed additional resources that can be helpful in plotting an optimal path through vision care. Below is a list of such resources, including information on genetic testing, clinical trials, Vision Quest (the FFBs in-person educational events), and more. The list will update as new resources are added.
Must-Read Resources Vision Quest Educational Series
We know that helpful resources related to your eye disease can be difficult to find. Vision care in Canada entails a complex web of services, programs, and instructions, and little of it is centralized. The information on this site represents our attempt at providing a comprehensive, centralized resource that offers guidance and information specific to your eye disease. Our goal is to help you find your optimal path through vision care in Canada, which is why we call this initiative Vision Care Pathways.
December 12th, 2018 by FFB Canada
Right now, over 1 million Canadians are living with blinding eye diseases and as vision fades, so too can hope. To date, donors of the Foundation Fighting Blindness (FFB) have contributed more than $32 million for vision research. And now, until the end of 2018, a generous supporter will match your gift up to a
November 13th, 2018 by FFB Canada
On Saturday, October 20, 2018, family and friends of the Celebres came together in support of one very special little boy. Nicholas Celebre was born with Usher syndrome,a condition that causes deaf-blindness and often balance issues. Born profoundly deaf, he was fortunate enough to get cochlear implants when he was 12 months old. He also
November 13th, 2018 by FFB Canada
Guest-written by Deborah Scott. Our daughter, Olivia was 5 years old when she was diagnosed with a blinding eye disease called retinitis pigmentosa (RP). It was difficult for us to comprehend what that diagnosis really meant. As a parent, you never get over the impact of learning that there is so much more to vision
See the original post here:
Retinitis Pigmentosa - The Foundation Fighting Blindness
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - November 29th, 2020
- Cancer Stem Cell Therapy Market Research Report 2020 By Segmentations, Key Company Profiles and Demand Forecasts to 2026 - The Market Feed - November 29th, 2020
- Human Embryonic Stem Cell (hESC) Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026 - The Market... - November 29th, 2020
- Stem Cell Assay Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - Cheshire Media - November 29th, 2020
- Asia Pacific Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User,... - November 27th, 2020
- Global Animal Stem Cell Therapy Market Research Report by Size, Data, Developments, Global Demand, In-Depth Analysis and Forecast 2020 to 2025 |... - November 27th, 2020
- Europe Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User, and... - November 27th, 2020
- Scaffold Technology Market Research Report by Product, by Application, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... - November 27th, 2020
- The Thorough Analysis Of The Global Stem Cell Media market Research During COVID-19 Health Crisis - The Courier - November 27th, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 27th, 2020
- Global Live Cell Imaging Market Report 2020-2025: Market Size is Projected to Reach USD 2.8 Billion by 2025 from USD 1.8 Billion in 2020 - PRNewswire - November 27th, 2020
- North America Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ; End User,... - November 27th, 2020
- Post-doctoral Fellow in Computational Stem Cell Biology job with THE UNIVERSITY OF HONG KONG | 234737 - Times Higher Education (THE) - November 27th, 2020
- Circulating Tumor Cells and Cancer Stem Cells Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026... - November 27th, 2020
- Analyzing Impacts of Covid-19 on Global Cell Culture Media Market Effects, Aftermath and Forecast To 2025 - The Courier - November 27th, 2020
- Accretion: Current and Future Business Analysis in Cell Expansion Market - PharmiWeb.com - November 27th, 2020
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - Cheshire Media - November 27th, 2020
- Stem Cell Market to Witness a Pronounce Growth During (2020-2026) Cheshire Media - Cheshire Media - November 27th, 2020
- Demand with COVID-19 impact analysis on Cell Expansion Market - The Courier - November 27th, 2020
- Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for... - November 27th, 2020
- Researchers grow first plant-based gel to help organoid development for biomedical applications - Microbioz India - November 27th, 2020
- California's stem cell research agency looks to the future - Bond Buyer - November 25th, 2020
- Unexpected discovery about stem cell immortality study - News - The University of Sydney - November 25th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 25th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 25th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - Yahoo Finance UK - November 25th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire - November 25th, 2020
- Middle East & Africa Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ;... - November 25th, 2020
- Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The... - November 25th, 2020
- New study on CRISPR: the stake of unintended consequences in embryos - BioNews - November 25th, 2020
- The Stem Cell Characterization and Analysis Tools Market to grow incomparably in the next decade - The Market Feed - November 25th, 2020
- New solution to kill coronavirus on common surfaces in seconds - University of California - November 25th, 2020
- Agricultural Equipment Market to Witness Robust Expansion Throughout the Forecast Period 2027 - re:Jerusalem - November 20th, 2020
- Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 - re:Jerusalem - November 12th, 2020
- The Canine Stem Cell Therapy Market To Move Away From Insipidness, Reach US$ 218.2 Mn - PRnews Leader - November 12th, 2020
- Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis - TMR Research Blog - November 12th, 2020
- Stem Cell Therapy Market Growth Analysis 2020 By Industry Top Manufacturers, Business Opportunities, Industry Growth, Size, Gross Margin, Regional... - November 12th, 2020
- Stem Cell Media Market 2020 Industry Analysis and Trends Forecast to 2026 Thermo Fisher, CellGenix, Lonza, STEMCELL Technologies, Corning - The Think... - November 12th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Projected to Grow Massively in Near Future - The Daily Philadelphian - November 12th, 2020
- Global Live Cell Imaging Markets, 2020-2025 - Growing Adoption of High-Content Screening Techniques in Drug Discovery - Yahoo Finance UK - November 12th, 2020
- GLOBAL STEM CELL MARKET FORECAST 2021-2028 - GlobeNewswire - November 12th, 2020
- Flow Cytometry Market Is Expected to Generate Revenue of US$ 11.3 billion by 2030, Globally - GlobeNewswire - November 12th, 2020
- Stem Cell Therapy Market 2020 to 2025: Business Development Strategies and Top Manufacturers Analysis : Anterogen Co., Ltd. (South Korea), MEDIPOST... - November 12th, 2020
- ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights - BioSpace - November 12th, 2020
- Stem Cell Characterization and Analysis Tool Market Size Analysis: Growth Factors, Share by Regional Production, Revenue and Regional Trends with Key... - November 12th, 2020
- Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Galveston County Daily News - November 12th, 2020
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - BCFocus - November 12th, 2020
- Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - PRNewswire - November 12th, 2020
- CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health... - November 12th, 2020
- Brain Development and Disorder Research Receives $1.5 Million NSF Boost - USC Viterbi School of Engineering - November 7th, 2020
- Many Initiatives Still Too Close to Call in California - Courthouse News Service - November 7th, 2020
- Election 2020: Californias ballot initiative system isnt working. - Vox.com - November 7th, 2020
- Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader - November 5th, 2020
- Cancer Stem Cell Therapeutics Market Outlooks 2020: Size, Cost Structures, Growth rate and Industry Analysis to 2027 - Eurowire - November 5th, 2020
- Biologics Safety Testing Market Research Report by Test Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo Finance... - November 5th, 2020
- Global Regenerative Medicine Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com -... - November 5th, 2020
- Stem Cell Media Market Projected to Witness Vigorous Expansion by 2027 - The Think Curiouser - November 5th, 2020
- Cell Isolation Market Research and Analysis by Expert: import/export details, Cost Structures and statistics till 2027 - KYT24 - November 5th, 2020
- MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition - PharmiWeb.com - November 5th, 2020
- The Many Model Systems of COVID-19 - The Scientist - November 5th, 2020
- Soybean Trypsin Inhibitor Market Brief Analysis and Application, Growth by 2026 | Biological Industries, Thermo Fisher Scientific, Sigma-Aldrich... - November 5th, 2020
- Cell and Tissue Culture Supplies Market Analysis with Market Size, Industry Share, trends and Forecast to 2026 - The Think Curiouser - November 5th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Madison.com - November 3rd, 2020
- A Review of Stem Cell-Based Therapies for Parkinson Disease - AJMC.com Managed Markets Network - November 3rd, 2020
- 10 health and science-focused races to watch on election night - STAT - November 3rd, 2020
- Animal Stem Cell Therapy Market 2020, Global Research Analysis Report Growth at CAGR Value, Industry Share, Key Company Profiles, Type, Applications,... - November 3rd, 2020
- Stem Cell Therapy Market To Exceed Revenues Worth US$ By The End Of 2020 2027 - Eurowire - November 3rd, 2020
- Stem Cell Banking Market Research Report 2020 By Segmentations, Key Company Profiles and Demand Forecasts to 2026 - Aerospace Journal - November 3rd, 2020
- Stem Cell Media Market Analysis And Demand With Forecast Overview To 2027 - Aerospace Journal - November 3rd, 2020
- Stem Cell Characterization and Analysis Tool Market : By Component, by Application, by Component Mode, and By Region Global Forecast up to 2026 -... - November 3rd, 2020
- Impact of COVID-19 on Plant Stem Cell For Cosmetics Market Overview with Detailed Analysis, Competitive Landscape & Forecast To 2026 - Eurowire - November 3rd, 2020
- 2020 Election Tracker: All The State Ballot Healthcare Initiatives - Forbes - November 3rd, 2020
- California Proposition 14 is about pikuach nefesh heres why - Forward - November 3rd, 2020
- Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth - BioSpace - November 3rd, 2020
- Stem Cell Alopecia Treatment Market Insights and Development Trends from 2020-2027 - Aerospace Journal - November 3rd, 2020
- Global Stem Cell Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - PRnews Leader - November 3rd, 2020
- Canine Stem Cell Therapy Market Shows Expected Trend to Guide from 2020-2026 with Growth Analysis by Manufacturers, Regions, Type and Application -... - November 3rd, 2020
- Survival Benefit of GVHD in MDS Is Limited to Specific Patient Subgroup - Cancer Therapy Advisor - November 3rd, 2020
- Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results - GlobeNewswire - November 3rd, 2020
- Meat-Tech 3D Ltd. Announces Successful $7 Million Funding Round led by Psagot Provident Funds and other leading institutional investors - PRNewswire - November 3rd, 2020